Akebia Therapeutics
Mar 8, 2016

Akebia to Host Conference Call on March 14th to Discuss Full-Year 2015 Financial Results and Corporate Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it will host a conference call on Monday, March 14, 2016 at 4:30 PM ET to discuss the financial results for the year ended December 31, 2015, and recent corporate highlights.

Conference Call and Webcast

Date:   March 14, 2016

Time:

4:30 PM ET

Telephone Access:

Domestic Callers: dial (877) 458-0977
International Callers: dial (484) 653-6724
Please reference the Akebia conference call
Passcode: 67706535

Online Access:

Go to the Investor Relations section of the Akebia website and follow instructions for accessing the live webcast. Please connect to the website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. An archived presentation will be available for 90 days.
 

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with chronic kidney disease (CKD) through hypoxia-inducible factor (HIF) biology. Akebia has commenced Phase 3 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD.

Akebia Therapeutics
Investors:
Susan Kim, 212-600-1902
Susan@argotpartners.com
or
Media:
Elizabeth Schleifstein, 917-763-8106
Eliza@argotpartners.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media